


# PRODUCT INFORMATION



**CYY292**

Item No. 39831

**CAS Registry No.:** 2644673-04-9  
**Formal Name:** N<sup>4</sup>-1H-indazol-6-yl-N<sup>2</sup>-[3-methoxy-4-(4-methyl-1-piperazinyl)phenyl]-5-methyl-2,4-pyrimidinediamine  
**MF:** C<sub>24</sub>H<sub>28</sub>N<sub>8</sub>O  
**FW:** 444.5  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥3 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

CYY292 is supplied as a solid. A stock solution may be made by dissolving the CYY292 in the solvent of choice, which should be purged with an inert gas. CYY292 is slightly soluble in ethanol and methanol.

## Description

CYY292 is an inhibitor of PDGFR $\alpha$ , PDGFR $\beta$ , FGFR1, -2, and -3, (IC<sub>50</sub>s = 5.35, 4.6, 28, 28, and 78 nM, respectively).<sup>1,2</sup> It is selective for these kinases over FGFR4 (IC<sub>50</sub> = >1,000 nM) but also inhibits c-Kit, VEGFR2, VEGFR1, and insulin-like growth factor 1 receptor (IGF-1R; IC<sub>50</sub>s = 67, 33, 36, and 75 nM, respectively), as well as EGFR, Bruton's tyrosine kinase (BTK), cyclin-dependent kinase 4 (Cdk4)/cyclin D3, and MET (IC<sub>50</sub>s = 128, 198, 214, and 396 nM, respectively).<sup>1</sup> CYY292 inhibits the proliferation of MG-63, U2OS, MNNG/HOS, and Saos-2 osteosarcoma cells (IC<sub>50</sub>s = 0.84, 0.76, 1.36, and 0.72  $\mu$ M, respectively).<sup>2</sup> It inhibits the migration and invasion of U87MG and LN-229 glioblastoma cells when used at concentrations of 0.3 and 0.5  $\mu$ M.<sup>1</sup> CYY292 (30 mg/kg) decreases tumor volume and increases survival in a U87MG orthotopic mouse xenograft model.

## References

1. Bi, Y., Zheng, R., Hu, J., *et al.* A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3 $\beta$ / snail signaling axis. *Genes Dis.* **11(1)**, 479-494 (2023).
2. Chen, X., Liu, L., Liu, P., *et al.* Discovery of potent and orally bioavailable platelet-derived growth factor receptor (PDGFR) inhibitors for the treatment of osteosarcoma. *J. Med. Chem.* **65(7)**, 5374-5391 (2022).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/09/2023

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM